Literature DB >> 30836158

A novel joint HCPMMP method for automatically classifying Alzheimer's and different stage MCI patients.

Jinhua Sheng1, Bocheng Wang2, Qiao Zhang3, Qingqiang Liu4, Yangjie Ma4, Weixiang Liu4, Meiling Shao4, Bin Chen4.   

Abstract

A 360-area surface-based cortical parcellation was recently generated using multimodal data in a group average of 210 healthy young adults from the Human Connectome Project (HCP). In order to automatically and accurately identify mild cognitive impairment (MCI) at its two levels (early MCI and late MCI), Alzheimer's disease (AD) and healthy control (HC), a novel joint HCP MMP method was first proposed to delineate the cortical architecture and function connectivity in a group of non healthy adults. The proposed method was applied to register a dataset of 96 resting-state functional connectomes from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to Connectivity Informatics Technology Initiative (CIFTI) space and parcellated brain into human connectome project multi-modal parcellation (HCPMMP) with 360 areas. Various network features in each node of the connectivity network were considered as the candidate features for classification.The fine-grained multi-modal based on HCP-MMP combined with machine learning in identification for EMCI, LMCI, AD and HC. Applying various network features, including strength, betweenness centrality, clustering coefficient, local efficiency, eigenvector centrality, etc, we trained and tested several machine learning models. Thousands of features were processed by filter and wrapper feature selection procedures, and finally there were thirty features to be selected to achieve classification accuracies of 93.8% for EMCI vs. HC, 95.8% for LMCI vs. HC, 95.8% for AD vs. HC, and 91.7% for LMCI vs. AD, respectively by using support vector machine (SVM) algorithm. Most of the selected features locate in the region of temporal or cingulate cortex. Compared with previous studies, our results demonstrate the superiority of the proposed method over existing techniques.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Alzheimer's disease (AD); Healthy control (HC); Human connectome project (HCP); Machine learning; Mild cognitive impairment (MCI); Multi-modal parcellation (MMP); Network-based analysis

Mesh:

Year:  2019        PMID: 30836158     DOI: 10.1016/j.bbr.2019.03.004

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  6 in total

1.  Parkinson's Disease Detection from Resting-State EEG Signals Using Common Spatial Pattern, Entropy, and Machine Learning Techniques.

Authors:  Majid Aljalal; Saeed A Aldosari; Khalil AlSharabi; Akram M Abdurraqeeb; Fahd A Alturki
Journal:  Diagnostics (Basel)       Date:  2022-04-20

2.  Connectivity and variability of related cognitive subregions lead to different stages of progression toward Alzheimer's disease.

Authors:  Jinhua Sheng; Bocheng Wang; Qiao Zhang; Margaret Yu
Journal:  Heliyon       Date:  2022-01-23

3.  Classification and Interpretability of Mild Cognitive Impairment Based on Resting-State Functional Magnetic Resonance and Ensemble Learning.

Authors:  Mengjie Hu; Yang Yu; Fangping He; Yujie Su; Kan Zhang; Xiaoyan Liu; Ping Liu; Ying Liu; Guoping Peng; Benyan Luo
Journal:  Comput Intell Neurosci       Date:  2022-08-19

4.  The trend of disruption in the functional brain network topology of Alzheimer's disease.

Authors:  Alireza Fathian; Yousef Jamali; Mohammad Reza Raoufy
Journal:  Sci Rep       Date:  2022-09-02       Impact factor: 4.996

5.  Identifying and characterizing different stages toward Alzheimer's disease using ordered core features and machine learning.

Authors:  Jinhua Sheng; Bocheng Wang; Qiao Zhang; Rougang Zhou; Luyun Wang; Yu Xin
Journal:  Heliyon       Date:  2021-06-11

6.  Searching for optimal machine learning model to classify mild cognitive impairment (MCI) subtypes using multimodal MRI data.

Authors:  Tatsuya Jitsuishi; Atsushi Yamaguchi
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.